Revvity (NYSE:RVTY) Price Target Lowered to $125.00 at Robert W. Baird

Key Points

• Robert W. Baird cut its price target on Revvity to $125 from $129 but kept an "outperform" rating, implying about a 44.08% upside from the prior close.
• Overall analyst consensus is a Hold with an average price target of $109.36 after several firms (JPMorgan, Goldman, Barclays) trimmed targets and moved to neutral/equal-weight.
• Revvity recently beat quarterly estimates—EPS $1.70 vs $1.55 expected and revenue $772.06M vs $759.81M, with revenue up 5.9% year‑over‑year.

Revvity (NYSE:RVTY - Get Free Report) had its target price decreased by analysts at Robert W. Baird from $129.00 to $125.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has an "outperform" rating on the stock. Robert W. Baird's price target would suggest a potential upside of 44.08% from the stock's previous close.

Several other equities research analysts also recently commented on RVTY. JPMorgan Chase & Co. reduced their target price on shares of Revvity from $105.00 to $96.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 31st. TD Cowen restated a "hold" rating on shares of Revvity in a research note on Tuesday, February 3rd. The Goldman Sachs Group reduced their target price on shares of Revvity from $110.00 to $95.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 14th. Barclays restated an "equal weight" rating and issued a $95.00 target price (down from $118.00) on shares of Revvity in a research note on Tuesday, April 14th. Finally, Wall Street Zen downgraded shares of Revvity from a "buy" rating to a "hold" rating in a research report on Saturday, April 18th. Three research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $109.36.

Revvity Trading Up 0.1%

Shares of Revvity stock opened at $86.76 on Monday. The firm has a market capitalization of $9.70 billion, a PE ratio of 41.71, a price-to-earnings-growth ratio of 1.85 and a beta of 1.05. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.68 and a quick ratio of 1.40. The company's fifty day moving average price is $90.39 and its two-hundred day moving average price is $96.82. Revvity has a 52-week low of $81.22 and a 52-week high of $118.30.

Revvity (NYSE:RVTY - Get Free Report) last announced its quarterly earnings results on Monday, February 2nd. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.55 by $0.15. The firm had revenue of $772.06 million for the quarter, compared to analyst estimates of $759.81 million. Revvity had a net margin of 8.45% and a return on equity of 7.92%. The business's revenue for the quarter was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.42 EPS. On average, analysts expect that Revvity will post 5.39 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in RVTY. EdgePoint Investment Group Inc. lifted its position in Revvity by 26.3% during the 3rd quarter. EdgePoint Investment Group Inc. now owns 8,574,280 shares of the company's stock worth $751,536,000 after buying an additional 1,784,620 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in Revvity by 127.0% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,751,612 shares of the company's stock valued at $171,921,000 after purchasing an additional 980,142 shares during the period. Norges Bank acquired a new position in Revvity during the 4th quarter valued at about $80,382,000. Morgan Stanley lifted its position in Revvity by 29.6% during the 4th quarter. Morgan Stanley now owns 2,844,464 shares of the company's stock valued at $275,202,000 after purchasing an additional 650,083 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in Revvity by 39.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,125,957 shares of the company's stock valued at $186,307,000 after purchasing an additional 596,436 shares during the period. Institutional investors and hedge funds own 86.65% of the company's stock.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.